Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Autologous hematopoietic cell transplantation (autoHCT) is considered standard-of-care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). In 2016, 8776 autoHCTs were performed for MM in the United States (US), increasing from 5621 in 20101. With advances in supportive care resulting in outcomes comparable to those of younger patients, there is an increasing use of autoHCT in older patients [2,3]. Patients aged ≥70 years represented 12% of the over 14,000 autoHCTs performed in 20162.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research